Tremfya is the first and only fully-human, dual-acting IL-23p19 subunit inhibitor approved in both ulcerative colitis and ...

Patients with severe bowel disease are set to benefit from a new drug that can eliminate their distressing symptoms in only three months. The once-a-month jab, guselkumab, treats Crohn’s and ...

Subcutaneous guselkumab showed significant clinical remission and endoscopic response in moderate to severe Crohn's disease, with no added safety concerns. The GRAVITI study supported guselkumab's ...

If you have Crohn’s disease, the right medications may keep your condition under control. Some may even push your disease into remission, which means you won’t have any symptoms for a certain ...

Johnson & Johnson (J&J) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for its dual-acting IL-23 inhibitor Tremfya (guselkumab) in Crohn’s disease (CD) and ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) to treat Crohn’s disease and ulcerative colitis (UC). The approval was granted on 16th May, 2025 to ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s disease and ulcerative colitis (UC). Already used for plaque psoriasis and ...

However, clinical studies have shown that guselkumab is also efficacious in treating adults with moderately to severely active Crohn’s disease and UC who have not responded well to other ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 16 May 2025, approved guselkumab (Tremfya) to treat Crohn's disease and ulcerative colitis (UC). Guselkumab is currently ...

Guselkumab European Commission approval in Crohn's disease builds upon recent ulcerative colitis approval, 4 marking the fourth indication for this dual-acting IL-23 inhibitor in the European Union.

A Phase 2/3, randomised, double-blind, placebo- and active-controlled, parallel-group, multicentre protocol to evaluate the efficacy and safety of guselkumab in participants with moderately to ...